Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06609161 | A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) | PHASE1 | COMPLETED | 18 | — | — | Jul 16, 2024 | Aug 8, 2024 | Sep 27, 2024 | 1 | United States |
| NCT06733688 | A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) | PHASE1 | COMPLETED | 36 | — | — | Mar 23, 2022 | Apr 15, 2022 | Dec 13, 2024 | 1 | United States |
Blood samples will be collected to determine the AUC0-Inf of tedizolid.
Blood samples will be collected to determine the AUC0-Last of tedizolid.
Blood samples will be collected to determine the Cmax of tedizolid.
Blood samples will be collected to determine the AUC0-t of tedizolid.
| Arm | Type | Description |
|---|---|---|
| Tedizolid Phosphate Oral Formulation 1 (Reference) | EXPERIMENTAL | Participants will receive oral Formulation 1 (Reference). |
| Tedizolid Phosphate Oral Formulation 2 (Test) | EXPERIMENTAL | Participants will receive oral Formulation 2 (Test). |
| Name | Type | Description |
|---|---|---|
| Tedizolid Phosphate Oral Formulation 1 (Reference) | DRUG | Formulation 1 (FM1) powder for oral suspension. |
| Tedizolid Phosphate Oral Formulation 2 (Test) | DRUG | Formulation 2 (FM2) powder for oral suspension. |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2 Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of or presence of risk factors for Tors...